DOI: http://dx.doi.org/10.18203/2320-6012.ijrms20202279

Using positron emission tomography - computed tomography imaging to distinguish of metastatic disease from second primary lung tumours in patients with non-small cell lung cancer

Ngo Minh Xuan, Huynh Quang Huy

Abstract


Background: In NSCLC patients with multiple lesions, the differentiation between metastases and second primary tumours has significant therapeutic and prognostic implications. The aim of this retrospective study was to investigate the potential of 18F-FDG PET to discriminate metastatic disease from second primary lung tumours.

Methods: Of 318 NSCLC patients between November 2015 and October 2018 at Bach Mai hospital, patients with a synchronous second primary lung cancer were selected. Patients with metastatic disease involving the lungs served as the control group. Maximum standardized uptake values (SUVs) measured with 18F-FDG PET were determined for two tumours in each patient. The SUVmax was determined and compared between the second primary group and metastatic disease group. Receiver-operating characteristic (ROC) curve analysis was performed to determine the sensitivity and specificity of the SUVmax for an optimal cut-off value.

Results: A total of 81 NSCLC patients (44 metastatic disease, 37 second primary cancer) were included for analysis. The SUVmax was significantly higher in patients with second primary cancer than in those with metastatic disease (7.53±4.33 vs 4.35±2.58, respectively, p<0.001). The area under the ROC curve was 0.81 and the odds ratio for the optimal cut-off was 7.52.

Conclusions: SUVmax from 18F-FDG PET images can be helpful in differentiating metastatic disease from second primary tumours in patients with synchronous pulmonary lesions. Further studies are warranted to confirm the consistency of these results.

 


Keywords


Metastatic disease, Non-small cell Lung cancer, Second primary tumour, SUVmax

Full Text:

PDF

References


Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clini Proceed. 2008 May 1;83(5):584-594.

Van Rens MT, Zanen P, de la Rivière AB, Elbers HR, van Swieten HA, van den Bosch JM. Survival in synchronous vs single lung cancer: upstaging better reflects prognosis. Chest. 2000 Oct 1;118(4):952-8.

Silvestri GA, Gould MK, Margolis ML, Tanoue LT, McCrory D, Toloza E, et al. Noninvasive staging of non-small cell lung cancer: ACCP evidenced-based clinical practice guidelines. Chest. 2007 Sep 1;132(3):178S-201S.

Leong PP, Koch WM, Reed A, Eisele D, Sidransky D, Jen J, et al. Distinguishing second primary tumors from lung metastases in patients with head and neck sauamous cell carcinoma. J Nat Cancer Inst. 1998 Jul 1;90(13):972-7.

Douglas WG, Rigual NR, Loree TR, Wiseman SM, Al-Rawi S, Hicks WL. Current concepts in the management of a second malignancy of the lung in patients with head and neck cancer. Curr Opin Otolaryngol Head Neck Surg. 2003 Apr 1;11(2):85-8.

Jeon SY, Ahn SH, Kim CH, Lim SM, Koh JS, Lee JC. Esophageal and laryngeal cancer incidentally found on [18F] fluorodeoxyglucose positron emission tomography/computed tomography during the staging workup for lung cancer. Clini Lung Cancer. 2008 Jul 1;9(4):230-1.

de Geus-Oei LF, van Krieken JH, Aliredjo RP, Krabbe PF, Frielink C, Verhagen AF, et al. Biological correlates of FDG uptake in non-small cell lung cancer. Lung Cancer. 2007 Jan 1;55(1):79-87.

Croft DR, Trapp J, Kernstine K, Kirchner P, Mullan B, Galvin J, et al. FDG-PET imaging and the diagnosis of non-small cell lung cancer in a region of high histoplasmosis prevalence. Lung Cancer. 2002 Jun 1;36(3):297-301.

Kubota K, Murakami K, Inoue T, Itoh H, Saga T, Shiomi S, et al. Additional value of FDG-PET to contrast enhanced-computed tomography (CT) for the diagnosis of mediastinal lymph node metastasis in non-small cell lung cancer: a Japanese multicenter clinical study. Ann Nucl Medi. 2011 Dec 1;25(10):777-86.

Lee SM, Park CM, Paeng JC, Im HJ, Goo JM, Lee HJ, et al. Accuracy and predictive features of FDG-PET/CT and CT for diagnosis of lymph node metastasis of T1 non-small-cell lung cancer manifesting as a subsolid nodule. Eur Radiol. 2012 Jul 1;22(7):1556-63.

Jalaguier-Coudray A, Villard-Mahjoub R, Delouche A, Delarbre B, Lambaudie E, Houvenaeghel G, et al. Value of dynamic contrast-enhanced and diffusion-weighted MR imaging in the detection of pathologic complete response in cervical cancer after neoadjuvant therapy: a retrospective observational study. Radiology. 2017 Aug;284(2):432-42.

Zhu A, Lee D, Shim H. Metabolic positron emission tomography imaging in cancer detection and therapy response. Semi Oncol. 2011 Feb 1;38(1):55-69.